Human aldosterone synthase (CYP11B2) and cortisol synthase (CYP11B1) have been exploited in inhibitor screening campaigns to identify treatments for cardiovascular disorders [31] and cortisol-related diseases [32], which affect specific cellular responses to compounds for drug development. Here, CYP11B1 is linked to cardiovascular disorder.